[go: up one dir, main page]

PE20040558A1 - Derivados de fluorobenzamidas como inhibidores selectivos de la monoamino oxidasa b - Google Patents

Derivados de fluorobenzamidas como inhibidores selectivos de la monoamino oxidasa b

Info

Publication number
PE20040558A1
PE20040558A1 PE2003000577A PE2003000577A PE20040558A1 PE 20040558 A1 PE20040558 A1 PE 20040558A1 PE 2003000577 A PE2003000577 A PE 2003000577A PE 2003000577 A PE2003000577 A PE 2003000577A PE 20040558 A1 PE20040558 A1 PE 20040558A1
Authority
PE
Peru
Prior art keywords
alkyl
selective inhibitors
fluorobenzamidas
derivatives
monoamine oxidase
Prior art date
Application number
PE2003000577A
Other languages
English (en)
Inventor
Synese Jolidon
Rene Wyler
Andrew William Thomas
Sarmiento Rosa Maria Rodriguez
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20040558A1 publication Critical patent/PE20040558A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/69—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/30—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN MEDICAMENTO QUE COMPRENDE UN COMPUESTO DERIVADO DE FLUOROBENZAMIDA DE FORMULA I DONDE R1 ES H, ALQUILO C1-C6, HIDROXI-(C1-C6)-ALQUILO; R2 ES ALQUILO C1-C6, -CO-NR8R9, -(CH2)n-NR8R9, ENTRE OTROS; R3 ES H, HALOGENO-(C1-C6)-ALQUILO, CIANO, ENTRE OTROS; R4, R5, R6 Y R7 SON H O FLUOR; R8 Y R9 SON CADA UNO H O ALQUILO C1-C6; m ES DE 1-3; n ES DE 0-3. SON COMPUESTOS PREFERIDOS: (S)-N-(1-CARBAMOIL-ETIL)-2-FLUORO-4-(3-FLUOROBENCILOXI)-BENZAMIDA; 2-[4-(3-FLUOROBENCILOXI)-2-FLUOROBENZAMIDO]ACETAMIDA Y (S)-N-(1-CARBAMOIL-2-HIDROXI-ETIL)-2-FLUORO-4-(3-FLUOROBENCILOXI)-BENZAMIDA. DCHOS COMPUESTOS SON INHIBIDORES SELECTIVOS MAO-B UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER O DEMENCIA SENIL
PE2003000577A 2002-06-12 2003-06-10 Derivados de fluorobenzamidas como inhibidores selectivos de la monoamino oxidasa b PE20040558A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02012484 2002-06-12

Publications (1)

Publication Number Publication Date
PE20040558A1 true PE20040558A1 (es) 2004-09-09

Family

ID=29724375

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000577A PE20040558A1 (es) 2002-06-12 2003-06-10 Derivados de fluorobenzamidas como inhibidores selectivos de la monoamino oxidasa b

Country Status (20)

Country Link
US (1) US6951884B2 (es)
EP (1) EP1515926B1 (es)
JP (1) JP4181540B2 (es)
KR (1) KR100641963B1 (es)
CN (1) CN1274669C (es)
AR (1) AR040253A1 (es)
AT (1) ATE427928T1 (es)
AU (1) AU2003236719B2 (es)
BR (1) BR0311719A (es)
CA (1) CA2489247A1 (es)
DE (1) DE60327074D1 (es)
ES (1) ES2322254T3 (es)
MX (1) MXPA04012511A (es)
PA (1) PA8575001A1 (es)
PE (1) PE20040558A1 (es)
PL (1) PL374545A1 (es)
RU (1) RU2314289C2 (es)
TW (1) TW200406201A (es)
UY (1) UY27842A1 (es)
WO (1) WO2003106380A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7321065B2 (en) 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US6979750B1 (en) 2003-04-18 2005-12-27 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
CA2554696C (en) * 2004-02-13 2009-06-30 Warner-Lambert Company Llc Androgen receptor modulators
MXPA06015169A (es) * 2004-07-08 2007-08-21 Warner Lambert Co Moduladores de androgenos.
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
WO2006127133A2 (en) 2005-04-01 2006-11-30 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
WO2007008963A1 (en) * 2005-07-13 2007-01-18 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US20090170886A1 (en) * 2005-08-08 2009-07-02 Pfizer Inc Androgen modulators
US8372885B2 (en) * 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
CN102816082B (zh) * 2010-01-29 2015-03-11 浙江大学 苯甲酰胺类衍生物及制备方法和应用
TWI518062B (zh) 2011-12-26 2016-01-21 迪愛生股份有限公司 具有２－氟苯基氧基甲烷構造之化合物
US9637466B2 (en) 2013-07-25 2017-05-02 Dic Corporation Liquid crystal compound having 2, 6-difluorophenyl ether structure and liquid crystal composition thereof
US10544365B2 (en) 2013-08-30 2020-01-28 Dic Corporation Nematic liquid crystal composition
CN105358538A (zh) 2013-10-03 2016-02-24 Dic株式会社 具有2,6-二氟苯醚结构的液晶性化合物及其液晶组合物
JP5910800B1 (ja) 2014-07-31 2016-04-27 Dic株式会社 ネマチック液晶組成物
US10253258B2 (en) 2014-07-31 2019-04-09 Dic Corporation Nematic liquid crystal composition
KR20170095311A (ko) * 2014-12-17 2017-08-22 메르크 파텐트 게엠베하 바이메소젠성 화합물 및 메소젠성 매질
CN108912029B (zh) * 2017-08-25 2021-10-01 广东东阳光药业有限公司 含氮杂环酰胺衍生物及其用途
CN110483324A (zh) * 2019-09-10 2019-11-22 深圳振强生物技术有限公司 沙芬酰胺杂质的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1332151C (en) 1988-01-28 1994-09-27 Roman Amrein Use of a benzamide to treat cognitive disorder
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
WO2003106380A2 (en) 2003-12-24
JP2005529176A (ja) 2005-09-29
ES2322254T3 (es) 2009-06-18
RU2005100755A (ru) 2005-08-10
AU2003236719A1 (en) 2003-12-31
WO2003106380A3 (en) 2004-03-11
PL374545A1 (en) 2005-10-31
MXPA04012511A (es) 2005-02-17
EP1515926B1 (en) 2009-04-08
KR20050009743A (ko) 2005-01-25
ATE427928T1 (de) 2009-04-15
JP4181540B2 (ja) 2008-11-19
AR040253A1 (es) 2005-03-23
TW200406201A (en) 2004-05-01
US6951884B2 (en) 2005-10-04
CN1659135A (zh) 2005-08-24
PA8575001A1 (es) 2003-12-30
CN1274669C (zh) 2006-09-13
AU2003236719B2 (en) 2008-06-05
CA2489247A1 (en) 2003-12-24
BR0311719A (pt) 2005-03-15
UY27842A1 (es) 2003-12-31
DE60327074D1 (de) 2009-05-20
EP1515926A2 (en) 2005-03-23
KR100641963B1 (ko) 2006-11-06
US20030236304A1 (en) 2003-12-25
RU2314289C2 (ru) 2008-01-10

Similar Documents

Publication Publication Date Title
PE20040558A1 (es) Derivados de fluorobenzamidas como inhibidores selectivos de la monoamino oxidasa b
MXPA03011981A (es) 3-fluoruro-pirrolidinas como agentes antidiabeticos.
PE20041079A1 (es) Acetil-2-hidroxi-1,3-diaminoalcanos
PE20070078A1 (es) Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa
AR040489A1 (es) Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen
AR041297A1 (es) Derivados de 4-pirrolidino- fenil- bencil eter
SE0104340D0 (sv) New compounds
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
PE20040666A1 (es) Derivados novedosos de piperidina
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
CR7436A (es) Hidroxietilaminas substituidas
UY25143A1 (es) Procedimiento para la preparacion de inhibidores de proteasas.
PE20030925A1 (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
NZ528997A (en) Sulfonamides
AR039651A1 (es) Derivados de isoquinolina
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
FR2847471B1 (fr) Composition comprenant au moins un derive d'acide carbamique ,son utilisation cosmetique et comme medicament
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
AR032622A1 (es) Compuestos de 4-amino-azepan-3-ona, composiciones farmaceuticas que los comprenden, intermediarios utiles en la sintesis de tales compuestos, procedimiento para la sintesis de dichos compuestos, y uso de tales compuestos en la fabricacion de medicamentos
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
PT732332E (pt) Benzotienilpiperazinas substituidas sua utilizacao como medicamentos e processos para a sua preparacao
PE20040534A1 (es) Medicamentos que comprenden tiofenos sustituidos y procedimientos para su preparacion

Legal Events

Date Code Title Description
FC Refusal